What happens during a Remicade infusion?
Remicade is a medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease [1]. It's given as an infusion, where the medicine is administered through a vein over several hours. This process can cause some common side effects, which we'll discuss below.
Common infusion-related side effects
When you receive a Remicade infusion, you might experience some side effects, such as:
- Fatigue or drowsiness
- Headache
- Chills
- Fever
- Muscle pain
- Nausea and vomiting
- Dizziness
These symptoms are usually mild and can be treated with over-the-counter medications or rest.
Serious infusion-related reactions
In rare cases, patients may experience a more severe reaction to the infusion. These reactions can include:
- Anaphylaxis (a severe allergic reaction) [2]
- Hypotension (low blood pressure)
- Angioedema (swelling in the face, lips, tongue, or throat)
- Bronchospasm (wheezing, coughing, or shortness of breath)
If you experience any of these symptoms, let your healthcare provider know immediately. They can provide treatment to manage the reaction and ensure your safety.
Infusion schedule and preparation
Remicade is dosed as an intravenous infusion in a healthcare setting, given by a medical professional. The infusion schedule varies depending on the patient's condition, but it is typically administered on a regular basis (every 4-8 weeks). Before each infusion, patients may need to complete paperwork and discuss any potential side effects or concerns with their healthcare provider.
Alternatives and considerations
Biosimilar alternatives to Remicade, such as biosimilar etanercept (Erelzi, Amjevita, or Cyltezo), may have different infusion protocols or schedules [3]. Your healthcare provider will discuss these options with you and determine which treatment path is best for your condition.
References
[1] Pfizer, Remicade (Infliximab) Full Prescribing Information, https://www.pfizer.com/news/important-safety-information/remicade
[2] [U. S. Food and Drug Administration. (2020, January). REMICADE (Infliximab) Injection [Package Insert]]
[3] DrugPatentWatch.com, Biosimilar etanercept: Erelzi (Erelzi), Amjevita (Amjevita), Cyltezo (Cyltezo), https://www.drugpatentwatch.com/biosimilar-etanercept